Cure Alzheimer's Fund 101

• 6.5 million Americans are living with Alzheimer’s in 2022. By 2050, this number is projected to rise to over 14 million.

• Two-thirds of Alzheimer’s patients are women

• In 2022, Alzheimer’s and dementia will cost the US $355 billion. By 2050, the number could rise to $1.1 trillion.

• Over 11 million Americans provide an estimated 15 billion hours in unpaid care for people with Alzheimer’s or other forms of dementia, valued at nearly $257 billion

• 1 in 3 seniors dies with Alzheimer’s or another form of dementia.

• CureAlz is dedicated to funding research with the highest probability of stopping, slowing and preventing Alzheimer’s disease. Our board covers all operating costs so that 100% of every donation can go directly to Alzheimer’s research.

• Since inception, CureAlz has directed over $150 million to Alzheimer’s research. This money has funded more than 500 projects at 78 world-class institutions around the globe.

• CureAlz requires collaboration among our funded researchers. Our Research Leadership Group meets annually as well as holding quarterly conference calls to discuss their work, the latest Alzheimer’s developments, and guide our research funding.

• CureAlz provides seed funding to get high-risk, high-reward projects off the ground that are deemed too risky for larger organizations like the National Institutes of Health.

• CureAlz primary focus is funding foundational research looking at the pathology of the disease. Most drug trials fail because we don’t fully understand how Alzheimer’s begins and spreads. CureAlz is striving to change that.

• CureAlz has received a perfect 4-star rating from the charity watchdog site Charity Navigator for the past 10 consecutive years.

• CureAlz is listed as a Platinum charity on Guidestar